TCT-762 Is a high pacing rate post TAVI associated with appropriate pacemaker utilisation? A real-world multi-centre retrospective analysis of pacemaker utilisation in patients paced following TAVI  by Holroyd, Eric W. et al.
Pacing insertion and utilisation data for 4 CoreValve TAVI centres
Centre A B C D
Total number of
TAVI cases
229 132 198 262
Overall pacing
rate % (p<0.05)
22.7 9.1* 24.7 16.8
Duration after
TAVI of PPM
(days)(p<0.05)
3.8 6.5* 3.4 4.6
Depth of implant
(mm)
6.7 8.1 7.0 7.2
Atrial pacing 6
weeks %
(p<0.05)
22.6 52* 43.5 16.5
Atrial pacing 6
months %
20.9 25.6 44.8 23
Atrial at latest
follow-up %
23.2 39 23 23.2
Ventricular pacing
6 weeks %
(p<0.05)
64.9 84.5* 79.7 59.2
Ventricular pacing
6 months %
43.4 69.6 81.4 59.1
Ventricular pacing
latest follow-up %
(p<0.05)
47.1 84.7* 78 62.2
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SConclusions: Patients with LF-LG aortic stenosis experience very high 2-year
mortality in the absence of valve replacement. Valve replacement with surgical or
trans-catheter approach results in improved 2-year survival and saves 1 life for every
3.6 patients treated with SAVR/TAVI. Data on outcomes of TAVI in these complex
patients continues to evolve and mandates heart team approach in clinical decision
making.
TCT-761
Usefulness of Activated Clotting Time Guided Heparin Administration in
Reducing Bleeding Events during Trans-femoral Transcatheter Aortic Valve
Implantation
Chiara Bernelli1, Alaide Chieffo2, Matteo Montorfano3, Francesco Maisano4,
Jaclyn Chan5, Gennaro Giustino1, Charis Costopoulos6, Ermelinda De Meo1,
Francesco Giannini7, Azeem Latib1, Mauro Carlino8, Filippo Figini6, Gill L. Buchanan1,
Remo D. Covello1, Chiara Gerli1, Annalisa Franco1, Eustachio Agricola1,
Pietro Spagnolo1, Micaela Cioni1, Ottavio Alﬁeri1, Antonio Colombo9
1SanRaffaele Scientiﬁc Institute, Milan, Italy, 2San Raffael Scientiﬁc Institute,Milan, Italy,
Milan, Italy, 3San Raffaele scientiﬁc institute, Milano, Milano, 4San Raffaele Hospital,
Milan, Italy, 5San Raffaele Scientiﬁc Institute, Milan, N/A, 6San Raffaele Scientiﬁc
Institute, Milano, Milano, 7San Raffaele scientiﬁc institute, Milano, Italy, 8N/A, Milan,
Italy, 9EMO GVM Centro Cuore Columbus/San Raffaele Hospital, Milan, Italy
Background: Bleeding after TAVI still remains a frequent and potentially serious
complication. A common cause of bleeding in this population might be represented by
excessive intraprocedural anticoagulation with heparin. Adjusted heparin dose
administration using baseline ACT guidance may reduce the risk of overdosing in this
frail population. The aim of our study is to evaluate the impact of the Activated
Clotting Time (ACT)-guided heparin administration on bleeding occurrence during
trans-femoral (TF) Transcatheter Aortic Valve Implantation (TAVI).
Methods: Among 362 patients undergoing TF-TAVI, heparin was administered
according to two strategies: baseline ACT (ACT-guided, n¼174) or patient's body
weight (non ACT-guided n¼188 patients). The primary study objective was 30-day
major bleeding occurrence as deﬁned by the Valve Academic Research Consortium
(VARC) criteria. Secondary objectives were any life-threatening and minor bleeding,
vascular complications, acute kidney failure, myocardial infarction, stroke, all-cause
and cardiovascular mortality at 30 days according to VARC.
Results: Bleeding occurred in 167 (46.1%) patients; of these 76 (21.0%) had major
bleeding. Of note, the ACT-guided group had a signiﬁcant lower occurrence of
major (7.5% vs. 33.5%, p <0.001), life-threatening (12.1% vs. 20.2%, p¼0.04) and
any bleeding (25.9% vs.64.9%, p <0.001). Conversely, no differences were noted in
the other secondary study objectives. Importantly, irrespective of the time the
procedure was performed (experience phase) and of the operator preference in heparin
administration, the ACT-guided strategy was associated with a signiﬁcant lower
occurrence of major bleeding at 30 days. Moreover, after multivariate adjustment for
potential confounders ACT-guided propensity, the absence of ACT guidance was
an independent predictor of major bleeding at 30 days [OR 6.4, 95%CI (2.3-17.9),
p< 0.001].
Conclusions: In our experience, ACT guidance in TF-TAVI was correlated with
a signiﬁcant lower occurrence of major, life-threatening and any bleeding. This
strategy might be an useful tool in reducing bleeding in this high-risk population.
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Background: Permanent pacemaker (PPM) requirement is a recognised complication
of Transcatheter Aortic Valve implantation (TAVI) (published rate of 16-40%) and
surgical aortic valve replacement(AVR)(8% of cases). PPM requirement post
CoreValve TAVI is inﬂuenced by 3 main factors: 1) electrocardiogram predictors, 2)
depth of CoreValve below annulus,3) timing of pacing decision. Early pacing
may allow earlier discharge but this may contribute to higher pacing rates.PPM uti-
lisation and how this relates to pacing rates in TAVI patients has not previously been
studied.
Methods: Data from a total of 821 consecutive patients treated between 2008 and
July 2012 with CoreValve in the four UK TAVI centres (A, B, C and D) was
examined. A retrospective analysis of all patients who received a pacemaker was
performed.
Results: Pre-TAVI electrocardiogram revealed a similar distribution of conduction
abnormalities in patients who required a PPM. Centre B had a signiﬁcantly (p<0.05)B232 JACC Vol 62/18/Suppl B j October 27–Novemberlower overall pacemaker rate (see table). All centres had a procedural management
strategy of high implantation of CoreValve. However, in patients receiving PPM, this
was not achieved and average depth of valve base from aortic annulus was measured
(Centre A 6.73mm, B 8.12mm, C 7.02mm and D 7.18mm, p¼NS). The decision to
pace was made signiﬁcantly later in centre B (mean of 6.5 days post TAVI compared
to 3.8 days in centre A, 3.4 days in centre C and 4.6 days in D, p<0.01), which may
then be reﬂected in the subsequent patient pacing requirement(see table).
Centre B recorded a signiﬁcantly lower overall pacing rate. This was associated
with a longer time taken for decision to pace but signiﬁcantly higher pacemaker
utilisation and less pacemaker redundancy.Conclusions: Pacing rates in each of the 4 centres was lower than previously reported
(9-24%vs 16-40%). In one centre, the pacing rate was similar to traditional surgery
(9%). Early PPM insertion (<3days) led to a higher PPM rate but low utilisation.
Whereas, a delay in decision to insert PPM appears to be associated with a lower
overall insertion rates and reduced redundancy in the inserted pacemakers.
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Background: Transcatheter aortic valve implantation (TAVI) is an increasingly
common procedure in elderly and multimorbid patients with aortic stenosis. A pre-
procedural risk evaluation scheme beyond current surgical risk scores has not been
widely implemented.
Methods: We developed a risk algorithm for 1-year mortality in two cohorts con-
sisting of 845 patients undergoing routine transapical or transfemoral TAVI proce-
dures by commercially available devices, mean age 80.96.5, 51% women. Clinically
available variables and surgical risk scores were determined at baseline. Multivariable
Cox regression related clinical data to mortality (n¼207 deaths).
Results: Age, sex, body mass index, estimated glomerular ﬁltration rate, hemoglobin,
pulmonary hypertension, and mean transvalvular gradient and left ventricular ejection
fraction at baseline were most strongly associated with mortality (C-statistic 0.66, 95%
conﬁdence interval [CI] 0.61 to 0.70, calibration Chi2 statistic¼ 6.51; p¼0.69). B-type
natriuretic peptide and troponin I were signiﬁcantly related to outcome after multi-
variable-adjustment, but did not improve the C-statistic. Frailty increased the C-
statistic to 0.71 (95% CI 0.65 to 0.76).
Conclusions: We present a speciﬁc risk evaluation tool derived and validated in
routine TAVI cohorts that predicts 1-year mortality better than the conventional
scoring systems. Biomarkers only marginally improved risk prediction. Our risk
algorithm may help to guide decision-making when TAVI is planned.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
